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Purpose
The benefits of reirradiation for head and neck cancer (HNC) have not been determined. 
This study evaluated the efficacy of reirradiation using intensity-modulated radiotherapy 
(IMRT) for recurrent or second primary HNC (RSPHNC) and identified subgroups for whom 
reirradiation for RSPHNC is beneficial. 
Materials and Methods
A total of 118 patients from seven Korean institutions with RSPHNC who underwent IMRT-
based reirradiation between 2006 and 2015 were evaluated through retrospective review 
of medical records. We assessed overall survival (OS) and local control (LC) within the radio-
therapy (RT) field following IMRT-based reirradiation. Additionally, the OS curve according 
to the recursive partitioning analysis (RPA) suggested by the Multi-Institution Reirradiation 
(MIRI) Collaborative was determined. 
Results
At a median follow-up period of 18.5 months, OS at 2 years was 43.1%. In multivariate 
analysis, primary subsite, recurrent tumor size, interval between RT courses, and salvage 
surgery were associated with OS. With regard to the MIRI RPA model, the class I subgroup 
had a significantly higher OS than class II or III subgroups. LC at 2 years was 53.5%. Multi-
variate analyses revealed that both intervals between RT courses and salvage surgery were 
prognostic factors affecting LC. Grade 3 or more toxicity and grade 5 toxicity rates were 
8.5% and 0.8%, respectively.
Conclusion
IMRT-based reirradiation was an effective therapeutic option for patients with RSPHNC, 
especially those with resectable tumors and a long interval between RT courses. Further, 
our patients’ population validated the MIRI RPA classification by showing the difference of 
OS according to MIRI RPA class.
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Introduction
Despite aggressive multidisciplinary management includ-
ing radiotherapy (RT), up to half of patients with locally 
advanced head and neck cancer (HNC) experience locore-
gional recurrence [1-3]. Although surgery was the best sal-
vage therapy option for such patients, only a few patients 
could be candidates for surgical resection due to unresectabil-
ity or inoperability associated with poor performance func-
tions and their comorbidities [4,5]. Thus, for these patients, 
reirradiation has been considered as a salvage therapy to 
improve outcomes, although the concern of severe toxicity 
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following reirradiation has remained [6].
With the widespread adoption of conformal RT techniques 
such as intensity-modulated RT (IMRT) and volume-modu-
lated arc therapy, the therapeutic ratio of reirradiation may 
have increased owing to the advanced technique using mul-
tiple small beamlets, which have an accurate target system 
for irregularly shaped tumors while simultaneously avoiding 
normal tissue [7,8]. Therefore, reirradiation in the modern 
advanced RT era has led to the expectation that the efficacy 
after reirradiation would be improved [9], and it has contrib-
uted to the frequent application of reirradiation using IMRT 
in clinical practice [10-12].
However, the efficacy of reirradiation in the IMRT era still 
remains unclear. In particular, difficulties associated with the 
selection of patients who would benefit from reirradiation 
and the potential for lethal toxicity following reirradiation are 
barriers to performing reirradiation. Therefore, we conducted 
a multi-institutional study to describe the efficacy of IMRT-
based reirradiation for recurrent or second primary HNC 
(RSPHNC) and to identify prognostic factors for which the 
benefit of reirradiation appears favorable. We also sought to 
externally validate the recursive partitioning analysis (RPA) 





We performed a multicenter, retrospective cohort study 
to assess the efficacy of IMRT-based reirradiation for HNC. 
The eligibility criteria were as follows: (1) adult patients 
(≥ 18 years) who had locoregional RSPHNC without distant 
metastasis (M0) based on histologic and/or radiographic 
evidence of progression of the disease treated with IMRT-
based reirradiation from January 1, 2006, to December 31, 
2015; (2) availability of a medical record related to the ini-
tial radiation dose; and (3) patients who previously received 
≥ 40 Gy RT at the reirradiation site. Information on the 
patients’ clinicodemographic characteristics, tumor charac-
teristics, and administered treatments was collected from 
their medical records. All institutions decided on re-irradi-
ation for patients with RSPHNC through each institution’s 
multidisciplinary discussion during a head and neck tumor 
conference, in which an otolaryngologist, radiation oncolo-
gist, medical oncologist, and radiologist participated. Finally, 
118 patients from seven institutions with recurrent (n=109) 
or second primary (n=9) HNC who underwent IMRT-based 
reirradiation were analyzed.  
2. Treatment outcomes and prognostic variables
The primary endpoint was 2-year overall survival (OS) 
rate, and the secondary endpoint was local control (LC) rate. 
OS period was calculated from the time of reirradiation for 
recurrence to the date of death from any cause, and freedom 
from local progression was defined as an absence of disease 
on histologic and radiographic evaluation from the reirradia-
tion. The prognostic factors associated with OS and LC were 
as follows: age, sex, Karnofsky performance status, initial 
subsite, initial histology, surgery at recurrence, tumor size at 
recurrence, interval between RT courses, and organ dysfunc-
tion at reirradiation. In addition, we divided patients into 
prognostic subgroups using the RPA according to the inter-
val between RT courses, resectability, and organ dysfunction 
defined by the MIRI Collaborative [13] and assessed OS by 
class. Additionally, the late toxicity following reirradiation 
was assessed by reviewing medical charts.
3. Statistical analysis
Actuarial estimates for OS and LC were calculated using 
the Kaplan-Meier methods. Log-rank test was used to com-
pare risk factors affecting survival and LC estimates in uni-
variate analysis. A Cox regression model was used to identify 
potential prognostic factors for OS and LC in univariate and 
multivariate analyses. All analyses were performed using 
IBM SPSS ver. 20.0 (IBM Corp., Armonk, NY).
4. Ethical statement
This study was approved by the institutional review 
board of each participating institution. The requirement for 
informed consent was waived. We carried out this research 
according to the principles expressed in the declaration of 
Helsinki. 
Results
1. Patient and treatment characteristics 
The median age when performing IMRT-based reirradia-
tion was 59 years (range, 20 to 90 years). Of the total patients, 
95 patients (80.5%) had squamous cell carcinoma and 82 
patients (69.5%) showed stage III/IV at initial presentation. 
The approach to the RSPHNC consisted of surgery for 40.7% 
(n=48; R0 resection in 29 patients and R1 resection in 19 
patients) and chemotherapy for 72.9% (n=86) of the patients. 
Fractionation of IMRT-based reirradiation was once daily 
for all patients. The treatment volume included focal field 
in 84.7%, which was defined by the gross tumor or surgical 
bed plus a margin of 0.5-1.0 cm, and radical field in 15.3%, 
encompassing the gross tumor or surgical bed with an elective 
high-risk area plus a margin of 0.5-1.0 cm. The median inter-
val period between RT courses was 29.4 months (range, 2.6 to 
293.4 months). The median initial RT total dose, IMRT-based 
reirradiation total dose, and cumulative RT dose were 66 Gy 
(range, 40.0 to 78.6 Gy), 59.4 Gy (range, 36.0 to 75.0 Gy), and 
124.9 Gy (range, 90.0 to 146.3 Gy), respectively. With regard 
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to RPA classes, class I, II, and III accounted for 21.2%, 75.4%, 
and 3.4%, respectively. The baseline characteristics of 118 
patients from seven institutions are summarized in Table 1. 
Furthermore, the baseline characteristics according to each 
institution are shown in S1 Table. 
2. Outcomes and prognostic factors 
The median duration of follow-up after IMRT-based reirra-
diation was 18.5 months (range, 1.4 to 98.0 months). Twenty-
nine patients (24.6%) remained alive at the time of the last 
observation. The median OS duration and 2-year OS rate 
were 20.1 months (range, 16.1 to 24.1 months) and 43.1%, 
Table 1.  Baseline characteristics 
Variable Total (n=118)
Initial presentation
    Age, median (range, yr) 56 (20-83)
    Sex 
        Male 92 (78.0)
        Female 26 (22.0)
    ECOG PS 
        0-1 110 (93.2)
        2-3 8 (6.8)
    Primary subsite 
        Nasopharynx 30 (25.4)
        Oropharynx 15 (12.7)
        Oral cavity 9 (7.6)
        Paranasal sinus/Nasal cavity 23 (19.5)
        Hypopharynx/Larynx 30 (25.4)
        Other (SG, UP) 11 (9.3)
    Histology 
        SCC 95 (80.5)
        Non-SCC 23 (19.5)
    Stage 
        I/II 31 (26.3)
        III 16 (13.6)
        IV 66 (55.9)
        Unevaluable 5 (4.2)
Initial treatment 
    Treatment modality 
        Definitive RT/CRT 52 (44.1)
        Surgery±PORT/CRT 48 (40.7)
        Induction CTx+Definitive RT/CRT 13 (11.0)
        Induction CTx+Surgery±PORT/CRT 3 (2.5)
        Preoperative RT/CRT+Surgery 2 (1.6)
    Initial RT total dose, median (range, Gy) 66.0 (40.0-78.6)
    Initial RT fractional dose,  2.0 (1.2-2.5)
      median (range, Gy)
Second presentation 
    Age, median (range, yr) 59 (20-90)
        < 60 63 (53.4)
        ≥ 60 55 (46.6)
    ECOG PS 
        0-1 105.0 (89.0)
        2-3 13.0 (11.0)
    Presentation type 
        Recurrent  109 (92.4)
        SP 9 (7.6)
    rStage 
        rT0Nany 25 (21.2)
        rT1Nany 13 (11.0)
        rT2Nany 11 (9.3)
        rT3Nany 19 (16.1)




    Failure type
        Local failure 74 (62.7)
        Regional failure 24 (20.3)
        Locoregional failure 20 (16.9)
    Recurrent or SP tumor size (cm) 
        Median, range 3.0 (0.5-11.0)
            < 3 54 (45.8)
            ≥ 3 64 (54.2)
    No. of recurrent or SP tumor 
        1 72 (61.0)
        ≥ 2 46 (39.0)
    Pre-existing organ dysfunction 
        No 110 (93.2)
        Yesa) 8 (6.8)
    RPA classb) 
        Class I 25 (21.2)
        Class II 89 (75.4)
        Class III 4 (3.4)
Second treatment 
    Salvage surgery 
        No 70 (59.3)
        Yesc) 48 (40.7)
    Chemotherapy 
        No 32 (27.1)
        Yes 86 (72.9)
    Reirradiation total dose (Gy) 
        Median (range) 59.4 (36.0-75.0)
        < 60 60 (50.8)
        ≥ 60 58 (49.2)
    Reirradiation fractional dose,  2.1 (1.8-4.0)
      median (range, Gy)
    Treatment volume of reirradiationd) 
        Focal field 100 (84.7)
        Radical field 18 (15.3)
    Cumulative RT dose,  124.9 (90.0-146.3)
       median (range, Gy)
(Continued to the next page)
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respectively (Fig. 1). The Kaplan-Meier curve of factors 
related to OS after reirradiation identified primary subsites 
(p < 0.001) (Fig. 2A), RSPHNC tumor size (p < 0.001) (Fig. 
2B), number of RSPHNC (p=0.041), interval between RT 
courses (p=0.007) (Fig. 2C), and performance of salvage sur-
gery for RSPHNC (p=0.002) (Fig. 2D) as significant factors. 
In a multivariate stepwise Cox regression model analysis, 
primary subsites (non-hypopharynx/larynx/oral cavity vs. 
hypopharynx/larynx/oral cavity; hazard ratio [HR], 0.457; 
p=0.001), tumor size of RSPHNC (≥ 3 cm vs. < 3 cm; HR, 
2.119; p=0.001), interval between RT courses (≥ 24 months vs. 
< 24 months; HR, 0.460; p < 0.001), and salvage surgery (yes 
vs. no; HR, 0.586; p=0.023) were confirmed as independent 
prognostic factors affecting OS. All results from the univari-
ate and multivariate Cox regression analyses related to OS 
are shown in Table 2.
Local progression within the reirradiation field was devel-
oped in 50 patients (42.4%). The median time to local failure 
and 2-year LC rate were 28.9 months (range, 8.23 to 49.57 
months) and 53.5%, respectively (Fig. 1). Both univariate and 
multivariate Cox regression models revealed that the inter-
val between RT courses (p=0.078 and p=0.011, respectively) 
and performance of salvage surgery for RSPHNC (p=0.026 
and p=0.042, respectively) were significant prognostic factors 
associated with LC (Table 2). Fig. 3A and Fig. 3B show the 
Kaplan-Meier LC curve according to the interval between 
RT courses (p=0.074) and performance of salvage surgery 
(p=0.023), respectively.
3. Survival validation according to MIRI RPA
We classified the patients into three prognostic classes ac-
cording to the time interval between RT courses (< 2 years vs. 
≥ 2 years), resectability (resected vs. unresected), and organ 
dysfunction (yes vs. no), as follows: those with interval > 2 
years between RT courses with resected tumors (class I, n=25), 
those with interval > 2 years between RT courses with unre-
sected tumors or with interval ≤ 2 years between RT courses 
without organ dysfunction (class II, n=89), and those with 
interval ≤ 2 years between RT courses with organ dysfunc-
tion (class III, n=4). The 2-year OS of each RPA class was 
65.5% in class I, 38.0% in class II, and 25.0% in class III and 
was statistically significant (p=0.001) (Fig. 2D). 
4. Toxicity
During IMRT-based reirradiation, no severe acute toxicity 
was recorded. At a median of 18.5 months after retreatment, 
grade ≥ 3 toxicity developed in 10 patients (8.5%), which 
consisted of grade 3 mucositis (n=2), interorgan fistula (n=4), 
dysphagia (n=2), and osteoradionecrosis (n=1) and grade 5 
carotid blowout (n=1). With respect to organ dysfunction, 6 
patients (5.1%) were tracheostomy-dependent, while 5 pati-
ents (4.2%) were feeding tube-dependent (Table 3). 
Discussion
Our multi-center cohort study showed a 2-year OS of 43.1% 
and a 2-year LC of 53.5% after IMRT-based reirradiation for 
RSPHNC. The RSPHNC patients with small size tumors, a 
resectable status, and long interval between RT courses had a 
significantly better survival than their counterparts. We also 
validated the MIRI RPA classification by showing that RPA 
class I had a higher OS than class II or III. Regarding LC, we 
identified the independent impact of the interval between RT 
courses and performance of salvage surgery.
Previously published literature on IMRT for HNC repor-
ted that IMRT provides better oncologic outcomes and less 
toxicities than conventional RT [14,15]. Extending that view-
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Table 1.  Continued
Variable Total (n=118)
    Interval between RT courses (mo) 
        Median (range) 29.4 (2.6-293.4)
        < 24 52 (44.1)
        ≥ 24 66 (55.9)
ECOG PS, Eastern Cooperative Oncology Group performance 
status; SG, salivary gland; UP, unknown primary; SCC, squamous  
cell carcinoma; RT, radiotherapy; CRT, chemoradiotherapy; PORT,  
postoperative radiotherapy; CTx, chemotherapy; SP, second pri-
mary; rStage, recurrent tumor and nodal stage; RPA, recursive 
partitioning analysis. a)Tracheostomy (n=6, 5.2%) or feeding 
tube dependence (n=2, 1.6%) prior to re-irradiation, b)Prognostic 
groups associated with overall survival according to RPA defined 
by the Multi-Institution Reirradiation (MIRI) Collaborative, c)Sal-
vage surgery was performed in R0 resection for 29 patients and 
R1 resection for 19 patients, d)Focal field included the gross tumor 
or surgical bed plus margin of 0.5-1.0 cm, whereas radical field 
encompassed the gross tumor or surgical bed with elective high 
risk area plus margin of 0.5-1.0 cm.  
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point for RSPHNC patients, survival after IMRT-based reirra-
diation showed an improvement compared to conventional 
conformal reirradiation. The landmark prospective reirradia-
tion trials in the pre-IMRT era including RTOG 9610 [16] and 
RTOG 9911 [17] reported that the 2-year OS ranged from 15% 
to 25% in patients who did not undergo salvage surgery. On 
the contrary, the MIRI group representatively showed an OS 
rate of 40% at 2 years following reirradiation of HNC in the 
IMRT era, which was 45% for postoperative patients and 36% 
for definitive patients [13]. Additionally, the Italy head and 
neck working group reported excellent outcomes of 44% OS 
at 5-year after reirradiation using advanced RT [18]. Of note, 
the current study showed that OS at 2 years was 43%, which 
was consistent with the abovementioned studies invol- 
ving IMRT-based reirradiation. The favorable OS in our 
study could have resulted not only from this modern advan- 
ced RT technique but also from the high proportion of 
patients in RPA class I and II (96%), those who underwent 
salvage surgery (41%), those with a longer interval RT course 
application (56%), and those with no organ dysfunction at 
reirradiation (93%). 
Specifically, our data supported that salvage surgery in 
Fig. 2.  Kaplan-Meier curve of overall survival rate according to primary subsite (A), tumor size of recurrent or second primary tumor 
(B), interval between radiotherapy (RT) courses (C), salvage surgery (D), and recursive partitioning analysis (RPA) classes defined by the 
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conjunction with IMRT reirradiation for RSPHNC improved 
OS and LC [13,19]. Surgical resection of RSPHNC could be 
an important factor considering that RSPHNC was gener-
ated from radioresistant clonogens after initial chemoradia-
tion [20,21]. Finally, removing macroscopic tumors is a way 
to enhance retreatment effectiveness owing to the limited 
dose of IMRT-based reirradiation for gross tumors since the 
adjacent organ around the tumor was already irradiated 
with a high dose during previous RT. It was suggested that 
when patients with RSPHNC expected medically operable 
and convincing problem, salvage surgery should be encour-
aged cautiously. The higher LC and OS were the result of the 
longer interval between RT courses. The appropriate time 
interval between RT treatments for performing reirradia-
tion is not established, although it depends on the relation 
between previous the irradiated dose to organs at risk and its 
tolerance dose associated with normal tissue damage repair 
[22,23]. Previous studies reported that a longer interval from 
the previous RT course contributed to improved outcomes 
[13,21,24,25]. This was explained by the fact that, the longer 
the interval between RT treatments, the greater the likeli-
hood of LC and the lesser the aggressiveness of recurrent dis-
ease. It is noteworthy that in our patient population, organ 
dysfunction was not a part of prognostic factors affecting OS 
since we had only 6.8% of all patients with organ dysfunc-
tion. It shows that there was a bias in patient selection for 
reirradiation at each institution. It could be presumed that a 
patient without organ dysfunction was selected for retreat-
ment with IMRT-based reirradiation.
We validated the MIRI RPA classification for the whole 
patients’ population. The RPA classification differentiated 
the survival between class I and II/II. This difference was 
statistically significant. MIRI RPA class I cohort (66%) had a 
superior 2-year OS than class II and III (38% and 25%, respec-
tively) cohorts. MIRI RPA class I might be the ideal subgroup 
who should undergo the active salvage treatment including 
IMRT reirradiation and/or surgical resection [13]. We found 
that the proposed RPA model might be applicable for our 
RSPHNC patient population and may help in patient selec-
tion for retreatment.
Reirradiation for RSPHNC is a challenging issue owing to 
an increased risk of severe toxicities including fatality [23]. 
The rate of severe and fatal late toxicity in these cohorts was 
8.5% and 0.8%, respectively, whereas previous prospective 
studies reported the severe toxicity ranging from 22% to 34% 
and fatality rates of 3.6% to 7.6%, respectively [16,17]. The 
amelioration of safety was likely attributed to not only the 
intensity-modulated technique, but also the conservative 
patient selection criteria of each institution prior to embark-
ing the reirradiation course. The MIRI Collaborative group 
reported that in the modern reirradiation era, the risk of pro-
gression or death (64%) is four times the incidence of severe 
late toxicity following reirradiation (17%) [26]. Such risk of 
late toxicity was more dependent on patient or disease fac-
tors than treatment factors. This implied that future research 
related to patient selection benefiting from reirradiation is 
needed to elicit the effectiveness of reirradiation using mod-
ern technology including IMRT.








































Table 3.  Incidence of severe toxicity and organ dysfunction sta-
tus following IMRT-based reirradiation
Variable No. (%)
Grade ≥ 3 toxicity 10 (8.5)
    Grade 3 
        Mucositis 2 (1.7)
        Interorgan fistula 4 (3.4)
        Dysphagia 2 (1.7)
        Osteoradionecrosis 1 (0.8)
    Grade 5 
        Carotid blowout 1 (0.8)
Organ dysfunction 11 (9.3)
    Tracheostomy 6 (5.1)
    Feeding tube dependence  5 (4.2)
IMRT, intensity-modulated radiotherapy. 
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This current study has many limitations. The dominant 
weakness is in its retrospective nature and a heterogeneous 
population from multi-centers. Our cohort had various fea-
tures in terms of patient selection and treatment character-
istics according to the physician’s discretion. Further, other 
limitations were the small number of patients from each cen-
ter, which originated from the restriction of the cohort enroll-
ment period, and the inherent limitations of IMRT. We did 
not identify the prognostic impact of human papillomavirus 
(HPV) in patients [27], especially those with oropharyngeal 
cancer undergoing reirradiation due to the availability of the 
HPV status of only 10 patients.
In conclusion, our multi-institutional study showed that 
IMRT-based reirradiation with a median dose of 60 Gy con-
tributed to increased OS for patients with RSPHNC and 
had acceptable complications. Given the restricted salvage 
options, it could be considered an effective treatment for 
RSPHNC patients, especially those with small resectable 
tumors and a long interval between RT courses. Addition-
ally, our cohort confirmed the prognostic validity of the sur-
vival rate of the MIRI RPA classification.
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